Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Website: pfizer.com


  • Bad financial results growth rate -32.3% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (5.1%)
  • Dividend yield for the last twelve months 6.4%
  • Free cash flow yield 0.0% (LTM)
  • Share price is 6.3% higher than minimum and 55.7% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (164.3x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: PFE
Share price, USD:  (+2.3%)26.36
year average price 27.94  


year start price 28.40 2023-12-23

max close price 31.39 2024-07-30

min close price 24.80 2024-11-15

current price 26.36 2024-12-21
Common stocks: 5 615 000 000

Dividend Yield:  6.4%
EV / LTM EBITDA: 164.3x
EV / EBITDA annualized: 34.5x
Last revenue growth (y/y):  +4.3%
Last growth of EBITDA (y/y):  -68.9%
Historical revenue growth:  +11.7%
Historical growth of EBITDA:  -1.5%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 148 011
Net Debt ($m): 0
EV (Enterprise Value): 148 011
EBITDA LTM ($m): 901
EV / LTM EBITDA: 164.3x
Price to Book: 1.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-12-20businesswire.com

U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

2024-12-19fool.com

Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?

2024-12-18seekingalpha.com

Pfizer Momentum Shift Makes Me Less Bullish (Technical Analysis)

2024-12-18zacks.com

Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

2024-12-18forbes.com

Is Pfizer Stock Undervalued?

2024-12-17youtube.com

Pfizer climbs 4% on 2025 outlook

2024-12-17finbold.com

Here's why Pfizer (PFE) stock is surging

2024-12-17seekingalpha.com

Pfizer Inc. (PFE) Full-Year 2025 Financial Guidance Conference Call (Transcript)

2024-12-17investopedia.com

Pfizer Stock Rises as 2025 Outlook in Line With Expectations

2024-12-17schaeffersresearch.com

2 Pharma Stocks to Watch: Pfizer, Teva Pharmaceutical
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data